A retrospective study assessing DDR mutation status in patients treated with radium-223, investigating their association with efficacy and overall survival (OS) in metastatic castration-resistant prostate cancer
Latest Information Update: 13 Jul 2020
Price :
$35 *
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 13 Jul 2020 New trial record
- 04 Jul 2020 Primary endpoint (Overall survival) has been met according to the results published in the European Journal of Cancer
- 04 Jul 2020 Results published in the European Journal of Cancer